Stavudine-<sup>13</sup>C-d<sub>3</sub>

Stavudine-13C-d3

CAT N°: 28887
Price:

From 359.00 305.15

Stavudine-13C-d3 is intended for use as an internal standard for the quantification of stavudine (Item No. 14975) by GC- or LC-MS. Stavudine is an inhibitor of HIV reverse transcriptase and a derivative of the nucleoside thymidine (Item No. 20519).{53215} It inhibits HIV-1 replication in human peripheral blood mononuclear cells (PBMCs; EC50 = 8.8 nM). Stavudine reduces the synthesis of HIV-specific antigen in MT-4 cells when used at concentrations ranging from 0.1 to 10 µg/ml and reduces HIV-induced plaque formation in MT-4 cells at 0.05 µg/ml.{29420} It reduces plasma- and cell-associated viral load in macaques infected with a highly pathogenic isolate of HIV-2.{53216} Stavudine induces sustained hind paw mechanical allodynia in a rat model of antiretroviral toxic neuropathy (ATN) when administered at a dose of 75 mg/kg twice weekly for five consecutive doses for a cumulative dose of 375 mg/kg.{53217} Formulations containing stavudine, in combination with other antiretrovirals, have been used in the treatment of HIV-1 infection.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-(methyl-13C-d3)pyrimidine-2,4(1H,3H)-dione
  • Correlated keywords
    • avostav BMY 27857 BMU27857 D 4 T DHT Melxicap NSC 163661 NSC163661 sanilvudine stag stavir virostav zerit deuterated deuterium GCMS LCMS HIV1 MT4 HIV2 anti retroviral
  • Product Overview:
    Stavudine-13C-d3 is intended for use as an internal standard for the quantification of stavudine (Item No. 14975) by GC- or LC-MS. Stavudine is an inhibitor of HIV reverse transcriptase and a derivative of the nucleoside thymidine (Item No. 20519).{53215} It inhibits HIV-1 replication in human peripheral blood mononuclear cells (PBMCs; EC50 = 8.8 nM). Stavudine reduces the synthesis of HIV-specific antigen in MT-4 cells when used at concentrations ranging from 0.1 to 10 µg/ml and reduces HIV-induced plaque formation in MT-4 cells at 0.05 µg/ml.{29420} It reduces plasma- and cell-associated viral load in macaques infected with a highly pathogenic isolate of HIV-2.{53216} Stavudine induces sustained hind paw mechanical allodynia in a rat model of antiretroviral toxic neuropathy (ATN) when administered at a dose of 75 mg/kg twice weekly for five consecutive doses for a cumulative dose of 375 mg/kg.{53217} Formulations containing stavudine, in combination with other antiretrovirals, have been used in the treatment of HIV-1 infection.

We also advise you